Exacerbation of type II collagen-induced arthritis in apolipoprotein e-deficient mice in association with the expansion of th1 and th17 cells

Arthritis and Rheumatism

Volumn 63, Issue 4, 2011, Pages 971-980

  Postigo, Jorge ^a   Genre, Fernanda ^a   Iglesias, Marcos ^b   Fernández Rey, Maigualida ^a   Buelta, Luis ^a   Carlos Rodŕguez Rey, José ^a   Merino, Jesús ^a   Merino, Ramón ^c,d  

^a UNIVERSITY OF CANTABRIA   (Spain)

^b CSIC   (Spain)

^c University of Cantabria   (Spain)

^d UNIVERSITY OF CANTABRIA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E; COLLAGEN TYPE 2; FREUND ADJUVANT; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2A ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTHRITIS; ARTICLE; ATHEROSCLEROSIS; CELL EXPANSION; CLINICAL FEATURE; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; FEMALE; HISTOPATHOLOGY; HYPERLIPOPROTEINEMIA TYPE 3; IMMUNOGLOBULIN BLOOD LEVEL; LYMPH NODE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIODIAGNOSIS; REGULATORY T LYMPHOCYTE; TH1 CELL; TH17 CELL;

ANIMALS; ANTIBODIES; APOLIPOPROTEINS E; ARTHRITIS, EXPERIMENTAL; ATHEROSCLEROSIS; CELL PROLIFERATION; CHOLESTEROL; COLLAGEN; CYTOKINES; DISEASE MODELS, ANIMAL; LYMPH NODES; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; SEVERITY OF ILLNESS INDEX; T-LYMPHOCYTES, REGULATORY; TH1 CELLS; TH17 CELLS;

EID: 79953675378     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.30220     Document Type: Article

References (48)

1. Gonzalez-Gay MA, Gonzalez-Juanatey C, Martin J. Rheumatoid arthritis: a disease associated with accelerated atherogenesis. Semin Arthritis Rheum 2005;35:8-17. (Pubitemid 41111466)
2. Young A, Koduri G, Batley M, Kulinskaya E, Gough A, Norton S, et al. Mortality in rheumatoid arthritis. Increased in the early course of disease, in ischaemic heart disease and in pulmonary fibrosis. Rheumatology (Oxford) 2007;46:350-7. (Pubitemid 46189799)
3. Del Rincon ID, Williams K, Stern MP, Freeman GL, Escalante A. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 2001;44:2737-45. (Pubitemid 34016192)
4. Choi HK, Seeger JD. Lipid profiles among US elderly with untreated rheumatoid arthritis-the Third National Health and Nutrition Examination Survey. J Rheumatol 2005;32:2311-6. (Pubitemid 41780639)
5. Park YB, Lee SK, Lee WK, Suh CH, Lee CW, Lee CH, et al. Lipid profiles in untreated patients with rheumatoid arthritis. J Rheumatol 1999;26:1701-4. (Pubitemid 29367308)
6. Yoo WH. Dyslipoproteinemia in patients with active rheumatoid arthritis: effects of disease activity, sex, and menopausal status on lipid profiles. J Rheumatol 2004;31:1746-53.
7. Van Halm VP, Nielen MM, Nurmohamed MT, van Schaardenburg D, Reesink HW, Voskuyl AE, et al. Lipids and inflammation: serial measurements of the lipid profile of blood donors who later developed rheumatoid arthritis. Ann Rheum Dis 2007;66:184-8. (Pubitemid 46226052)
8. Mahley RW. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science 1988;240:622-30.
9. Hui DY, Harmony JAK, Innerarity TL, Mahley RW. Immunoregulatory plasma lipoproteins. Role of apoprotein E and apoprotein B. J Biol Chem 1980;255:11775-81. (Pubitemid 11132191)
10. Navab M, Hama SY, Cooke CJ, Anantharamaiah GM, Chaddha M, Jin L, et al. Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: step 1. J Lipid Res 2000;41:1481-94.
11. Navab M, Hama SY, Anantharamaiah GM, Hassan K, Hough GP, Watson AD, et al. Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: steps 2 and 3. J Lipid Res 2000;41:1495-508.
12. Daugherty A. Mouse models of atherosclerosis. Am J Med Sci 2002;323:3-10. (Pubitemid 34650115)
13. Fazio S, Linton MF. Mouse models of hyperlipidemia and atherosclerosis. Front Biosci 2001;6:D515-25.
14. Gustafsson K, Karlsson M, Andersson L, Holmdahl R. Structures on the I-A molecule predisposing for susceptibility to type II collagen-induced autoimmune arthritis. Eur J Immunol 1990;20: 2127-31. (Pubitemid 20355639)
15. Xie JJ, Wang J, Tang TT, Chen J, Gao XL, Yuan J, et al. The Th17/Treg functional imbalance during atherogenesis in ApoE(-/-) mice. Cytokine 2010;49:185-93.
16. Smith E, Prasad KM, Butcher M, Dobrian A, Kolls JK, Ley K, et al. Blockade of interleukin-17A results in reduced atherosclerosis in apolipoprotein E-deficient mice. Circulation 2010;121:1746-55.
17. Lubberts E, Koenders MI, Oppers-Walgreen B, van den Bersselaar L, Coenen-de Roo CJ, Joosten LA, et al. Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion. Arthritis Rheum 2004;50:650-9. (Pubitemid 38198849)
18. Sato K, Suematsu A, Okamoto K, Yamaguchi A, Morishita Y, Kadono Y, et al. Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J Exp Med 2006;203:2673-82. (Pubitemid 44833343)
19. Littman DR, Rudensky AY. Th17 and regulatory T cells in mediating and restraining inflammation. Cell 2010;140:845-58.
20. Asquith DL, Miller AM, Hueber AJ, Liew FY, Sattar N, McInnes IB. Apolipoprotein E-deficient mice are resistant to the development of collagen-induced arthritis. Arthritis Rheum 2010;62: 472-7.
21. Gonzalez J, Tamayo E, Santiuste I, Marquina R, Buelta L, Gonzalez-Gay MA, et al. CD4+CD25+ T cell-dependent inhibition of autoimmunity in transgenic mice overexpressing human Bcl-2 in T lymphocytes. J Immunol 2007;178:2778-86. (Pubitemid 46333155)
22. Sancho D, Gomez M, Viedma F, Esplugues E, Gordon-Alonso M, Garcia-Lopez MA, et al. CD69 downregulates autoimmune reactivity through active transforming growth factor-β production in collagen-induced arthritis. J Clin Invest 2003;112:872-82. (Pubitemid 38063745)
23. Lopez-Hoyos M, Marquina R, Tamayo E, Gonzalez-Rojas J, Izui S, Merino R, et al. Defects in the regulation of B cell apoptosis are required for the production of citrullinated peptide autoantibodies in mice. Arthritis Rheum 2003;48:2353-61. (Pubitemid 36959218)
24. Marquina R, Diez MA, Lopez-Hoyos M, Buelta L, Kuroki A, Kikuchi S, et al. Inhibition of B cell death causes the development of an IgA nephropathy in (New Zealand white × C57BL/6)F(1)- bcl-2 transgenic mice. J Immunol 2004;172:7177-85. (Pubitemid 38669162)
25. Khallou-Laschet J, Tupin E, Caligiuri G, Poirier B, Thieblemont N, Gaston AT, et al. Atheroprotective effect of adjuvants in apolipoprotein E knockout mice. Atherosclerosis 2006;184: 330-41. (Pubitemid 43049717)
26. Gonzalez-Navarro H, Abu Nabah YN, Vinue A, Andres-Manzano MJ, Collado M, Serrano M, et al. p19(ARF) deficiency reduces macrophage and vascular smooth muscle cell apoptosis and aggravates atherosclerosis. J Am Coll Cardiol 2010;55:2258-68.
27. Cho YG, Cho ML, Min SY, Kim HY. Type II collagen autoimmunity in a mouse model of human rheumatoid arthritis. Autoimmun Rev 2007;7:65-70.
28. Campbell IK, Hamilton JA, Wicks IP. Collagen-induced arthritis in C57BL/6 (H-2b) mice: new insights into an important disease model of rheumatoid arthritis. Eur J Immunol 2000;30: 1568-75. (Pubitemid 30342798)
29. Kelly ME, Clay MA, Mistry MJ, Hsieh-Li H-M, Harmony JAK. Apolipoprotein E inhibition of proliferation of mitogen-activated T lymphocytes: production of interleukin 2 with reduced biological activity. Cell Immunol 1994;159:124-39. (Pubitemid 24381044)
30. Lynch JR, Tang W, Wang H, Vitek MP, Bennett ER, Sullivan PM, et al. APOE genotype and an ApoE-mimetic peptide modify the systemic and central nervous system inflammatory response. J Biol Chem 2003;278:48529-33. (Pubitemid 41079490)
31. Lee SI, Lee SY, Yoo WH. Association of apolipoprotein E polymorphism with bone mineral density in postmenopausal women with rheumatoid arthritis. Rheumatology (Oxford) 2005; 44:1067-8. (Pubitemid 41487185)
32. Gruaz L, Delucinge-Vivier C, Descombes P, Dayer JM, Burger D. Blockade of T cell contact-activation of human monocytes by high-density lipoproteins reveals a new pattern of cytokine and inflammatory genes. PLoS ONE 2010;5:e9418.
33. Saad AF, Virella G, Chassereau C, Boackle RJ, Lopes-Virella MF. OxLDL immune complexes activate complement and induce cytokine production by MonoMac 6 cells and human macrophages. J Lipid Res 2006;47:1975-83. (Pubitemid 44401985)
34. Lopes-Virella MF, Virella G. Clinical significance of the humoral immune response to modified LDL. Clin Immunol 2010;134: 55-65.
35. Charles-Schoeman C, Watanabe J, Lee YY, Furst DE, Amjadi S, Elashoff D, et al. Abnormal function of high-density lipoprotein is associated with poor disease control and an altered protein cargo in rheumatoid arthritis. Arthritis Rheum 2009;60:2870-9.
36. Yanaba K, Hamaguchi Y, Venturi GM, Steeber DA, St Clair EW, Tedder TF. B cell depletion delays collagen-induced arthritis in mice: arthritis induction requires synergy between humoral and cell-mediated immunity. J Immunol 2007;179:1369-80.
37. Svensson L, Jirholt J, Holmdahl R, Jansson L. B cell-deficient mice do not develop type II collagen-induced arthritis (CIA). Clin Exp Immunol 1998;111:521-6. (Pubitemid 28160894)
38. Fossati-Jimack L, Ioan-Facsinay A, Reininger L, Chicheportiche Y, Watanabe N, Saito T, et al. Markedly different pathogenicity of four immunoglobulin G isotype-switch variants of an antierythrocyte autoantibody is based on their capacity to interact in vivo with the low-affinity Fc receptor III. J Exp Med 2000;191:1293-302. (Pubitemid 30227118)
39. Ravetch JV, Bolland S. IgG Fc receptors. Annu Rev Immunol 2001;19:275-90. (Pubitemid 32368037)
40. Neuberger MS, Rajewsky K. Activation mouse complement by monoclonal mouse antibodies. Eur J Immunol 1981;11:1012-16. (Pubitemid 12212156)
41. Chu CQ, Song Z, Mayton L, Wu B, Wooley PH. IFNΥ deficient C57BL/6 (H-2b) mice develop collagen induced arthritis with predominant usage of T cell receptor Vβ6 and Vβ8 in arthritic joints. Ann Rheum Dis 2003;62:983-90. (Pubitemid 37159498)
42. Guedez YB, Whittington KB, Clayton JL, Joosten LA, van de Loo FA, van den Berg WB, et al. Genetic ablation of interferon-Υ up-regulates interleukin-1β expression and enables the elicitation of collagen-induced arthritis in a nonsusceptible mouse strain. Arthritis Rheum 2001;44:2413-24. (Pubitemid 32977511)
43. Manoury-Schwartz B, Chiocchia G, Bessis N, Abehsira-Amar O, Batteux F, Muller S, et al. High susceptibility to collagen-induced arthritis in mice lacking IFN-Υ receptors. J Immunol 1997;158: 5501-6. (Pubitemid 127681259)
44. Vermeire K, Heremans H, van de Putte M, Huang S, Billiau A, Matthys P. Accelerated collagen-induced arthritis in IFN-Υ receptor- deficient mice. J Immunol 1997;158:5507-13.
45. Lamacchia C, Palmer G, Seemayer CA, Talabot-Ayer D, Gabay C. Enhanced Th1 and Th17 responses and arthritis severity in mice with a deficiency of myeloid cell-specific interleukin-1 receptor antagonist. Arthritis Rheum 2010;62:452-62.
46. Notley CA, Inglis JJ, Alzabin S, McCann FE, McNamee KE, Williams RO. Blockade of tumor necrosis factor in collageninduced arthritis reveals a novel immunoregulatory pathway for Th1 and Th17 cells J Exp Med 2008;205:2491-7.
47. Elliott MJ, Maini RN, Feldmann M, Kalden JR, Antoni C, Smolen JS, et al. Treatment with a chimaeric monoclonal antibody to tumour necrosis factor α suppresses disease activity in rheumatoid arthritis: results of a multi-centre, randomised, double blind trial. Lancet 1994;344:1105-10.
48. Schottelius AJ, Moldawer LL, Dinarello CA, Asadullah K, Sterry W, Edwards CK III. Biology of tumor necrosis factor-α-implications for psoriasis. Exp Dermatol 2004;13:193-222. (Pubitemid 38618076)